Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Nashan, Bjorn ^a   Schemmer, Peter ^b   Braun, Felix ^c   Dworak, Markus ^d   Wimmer, Peter ^d   Schlitt, Hans ^e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Early initiation; Everolimus; HCC; Liver transplantation; MELD

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION FORMULA; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COCKCROFT GAULT FORMULA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; END STAGE LIVER DISEASE; FEMALE; GERMANY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HOEK FORMULA; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MODIFICATION OF DIET IN RENAL DISEASE; MORTALITY; MULTICENTER STUDY; NEUROTOXICITY; POSTOPERATIVE PERIOD; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GRAFT REJECTION; KIDNEY; KIDNEY FAILURE, CHRONIC; METHODOLOGY; MIDDLE AGED;

ADULT; CALCINEURIN INHIBITORS; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; EVEROLIMUS; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MIDDLE AGED; RESEARCH DESIGN; SIROLIMUS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84926285133     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0626-0     Document Type: Article

References (35)

1. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe: a report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675-88.
2. German foundation for organ transplantation. Assessed in December 2014, at [ http://www.dso.de/servicecenter/krankenhaeuser/transplantationszentren.html ]
3. AQUA German Hospital Quality Report 2012. Assessed in December 2014, at [ http://www.sqg.de/sqg/upload/CONTENT/EN/Quality-Report/AQUA-German-Hospital-Quality-Report-2012.pdf ].
4. Nijboer A, Ulrich F, Bechstein WO, Schnitzbauer AA. Volume and outcome relation in German liver transplant centers: what lessons can be learned? Transpl Res. 2014;3:5.
5. Weismuller TJ, Negm A, Becker T, Barg-Hock H, Klempnauer J, Manns MP, et al. The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int. 2009;22:970-8.
6. Schlitt HJ, Loss M, Scherer MN, Becker T, Jauch KW, Nashan B, et al. Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres. Z Gastroenterol. 2011;49:30-8.
7. Bahra M, Neuhaus P. Liver transplantation in the high MELD era: a fair chance for everyone? Langenbecks Arch Surg. 2011;396:461-5.
8. Rahmel A. Eurotransplant annual report 2012. Published annually by annual report/Eurotransplant International Foundation. Leiden: Eurotransplant Foundation. -III., graf., tab.
9. Braun F, Teren K, Wilms P, Gunther R, Allmann J, Broering DC, et al. Quality of life after liver transplantation. Transplant Proc. 2009;41:2564-6.
10. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-40.
11. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int. 2009;22:49-60.
12. Nashan B. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Clin Transplant. 2013;27 Suppl 25:16-29.
13. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9:741-7.
14. Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros AT, Turrion VS, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transpl Proc. 2003;35:1907-8.
15. Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;845438.
16. Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Saemann MD, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23:97-125.
17. Nashan B, Gaston R, Emery V, Saemann MD, Mueller NJ, Couzi L, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075-85.
18. Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547-61.
19. Nashan B. mTOR inhibitors and their role in modern concepts of immunosuppression. World J Surg. 2014;38:3199-201.
20. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640-8.
21. Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252-62.
22. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant. 2012;12:1855-65.
23. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014;14:701-10.
24. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008-20.
25. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734-45.
26. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, et al. Indications and management of everolimus after liver transplantation. Transplant Proc. 2009;41:2172-6.
27. Casanovas T, Argudo A, Pena-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. Transplant Proc. 2011;43:2216-9.
28. Castroagudin JF, Molina E, Romero R, Otero E, Tome S, Varo E. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15:1792-7.
29. De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int. 2009;22:279-86.
30. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15:1262-9.
31. Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011;17:905-13.
32. Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transpl. 2011;25:660-9.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-70.
34. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline E6. Note for Guidance on good clinical practice (GCP). Published by the European Medicines Agency, 7 Westferry Circus, London, UK. Assessed in December 2014, at. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
35. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly Helsinki, Finland, June 1964, amended by 48th General Assembly, Somerset West, South Africa 1996. JAMA. 1997;277:925-6.